Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
申请人:F. HOFFMANN-LA ROCHE LTD
公开号:US20130102600A1
公开(公告)日:2013-04-25
The present invention relates to a compound having the general formula I, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof,
which is useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
Alkyne Linchpin Strategy for Drug:Pharmacophore Conjugation: Experimental and Computational Realization of a <i>Meta</i>-Selective Inverse Sonogashira Coupling
作者:Sandip Porey、Xinglong Zhang、Suman Bhowmick、Vikas Kumar Singh、Srimanta Guin、Robert S. Paton、Debabrata Maiti
DOI:10.1021/jacs.9b10646
日期:2020.2.26
with sp3-rich 3D-fragments and natural products. This is accomplished through a template-assisted inverse Sonogashirareaction that displays high levels of selectivity for the meta-position. This protocol is also amenable to distal structural modifications of α-amino acids. The transformation of alkyne functionality to other functional groups further highlights the applicative potential. Computational
[EN] BENZOTHIAZOLE COMPOUNDS<br/>[FR] COMPOSÉS DE BENZOTHIAZOLE
申请人:INST MEDICAL W & E HALL
公开号:WO2009039553A1
公开(公告)日:2009-04-02
The present invention relates to benzothiazole compounds that mimic the activity of BH3 only proteins and are capable of binding to and neutralizing pro survival Bcl 2 proteins. The invention also relates to the use of such compounds in the regulation of cell death or cell survival and the treatment and/or prophylaxis of diseases or conditions associated with the deregulation of cell death or cell survival.
The sulfoneamide compounds having the following Formula (1), which can be used as an effective component of a CaSR antagonizing agent useful for prophylaxis and/or treatment of bone disorders including osteoporosis and etc., are provided. The compounds have an excellent activity of promoting PTH secretion. In addition, the compounds are useful as an effective component of a medicament for the prophylaxis and/or treatment of bone disorders such as osteoporosis, bone fracture, hypoparathyroidism and the like.
Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of 5-lipoxygenase (5-LO). Also described herein are methods of using such 5-LO inhibitors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions, diseases, or disorders.